Paula Pohlmann

Peer-Reviewed Articles

1. Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J; I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell 40(6):609-23, 2022. e-Pub 2022. PMID: 35623341.
2. Onzi GR, D'Agustini N, Garcia SC, Guterres SS, Pohlmann PR, Rosa DD, Pohlmann AR. Chemobrain in breast cancer: mechanisms, clinical manifestations, and potential interventions. Drug Saf 45(6):601-21, 2022. e-Pub 2022. PMID: 35606623.
3. Jones BC, Pohlmann PR, Clarke R, Sengupta S. Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux. Cancer Metastasis. e-Pub 2022. PMID: 35419769.
4. Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer 8(1):18, 2022. PMID: 35173164.
5. Lynce F, Blackburn MJ, Zhuo R, Gallagher C, Hahn OM, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann PR, Dilawari A, Tiwari SR, Chitalia A, Warren R, Tan M, Shajahan-Haq AN, Isaacs C. Hematological safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer 127(19):3622-3630, 2021. e-Pub 2021. PMID: 34157782.
6. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer 7(1):131, 2021. PMID: 34611148.
7. Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat 189(1):103-10, 2021. e-Pub 2021. PMID: 34120223.
8. Xiao J, Pohlmann PR, Isaacs C, Weinberg BA, He AR, Schlegel R, Agarwal S. Circulating tumor cells: technologies and their clinical potential in cancer metastasis. Biomedicines 9(9):1111, 2021. PMID: 34572297.
9. Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol 39(21):2375-85, 2021. e-Pub 2021. PMID: 34077270.
10. Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Asch F, Tan M, Isaacs C, Swain SM. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat 185(3):863-868, 2021. e-Pub 2021. PMID: 33400034.
11. Gallanis GT, Pericas RI, Riegel AT, Pohlmann PR. An evaluation of palbociclib as a breast cancer treatment option: a current update. Expert Opin Pharmacother 22(3):281-90, 2021. PMID: 33198527.
12. Heeke AL, Xiu J, Elliott A, Korn WM, Lynce F, Pohlmann PR, Isaacs C, Swain SM, Vidal G, Schwartzberg LS, Tan AR. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Res Treat 184(2):265-275, 2020. e-Pub 2020. PMID: 32776290.
13. Doucette K, Lai C, Pohlmann PR. Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer. Breast J 26(10):2031-2033, 2020. e-Pub 2020. PMID: 32639043.
14. Xiao J, McGill JR, Stanton K, Kassner JD, Choudhury S, Schlegel R, Sauna ZE, Pohlmann PR, Agarwal S. Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 32998338.
15. Khoury K, Tan AR, Elliott A, Xiu J, Gatalica Z, Heeke AL, Isaacs C, Pohlmann PR, Schwartzberg LS, Simon M, Korn WM, Swain SM, Lynce F. Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. Front Oncol 10:1475, 2020. e-Pub 2020. PMID: 32983983.
16. Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF, Madhavan S. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open 2(4):505-515, 2019. e-Pub 2019. PMID: 32025647.
17. Lynce F, Wang H, Petricoin EF, Pohlmann PR, Smaglo B, Hwang J, He AR, Subramaniam DS, Deeken J, Marshall J, Pishvaian MJ. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. Cancer Chemother Pharmacol 84(5):1145-1151, 2019. e-Pub 2019. PMID: 31538230.
18. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 175(3):595-603, 2019. e-Pub 2019. PMID: 30852761.
19. Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, Translational Breast Cancer Research Consortium. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 37(13):1081-1089, 2019. e-Pub 2019. PMID: 30860945.
20. Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R, Powderly J. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol 5(3):334-342, 2019. PMID: 30347025.
21. Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL. Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 79(4):874, 2019. PMID: 30770369.
22. Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer 5:2, 2019. e-Pub 2019. PMID: 30675512.
23. Lynce F, Saleh M, Shajahan-Haq A, Gallagher C, Dilawari A, Hahn O, Abu-Khalaf M, Cai L, Pohlmann P, Mohebtash M, Kamugisha L, Isaacs C. PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemp Clin Trials Commun 10:190-192, 2018. e-Pub 2018. PMID: 30009277.
24. Lynce F, Blackburn MJ, Cai L, Wang H, Rubinstein L, Harris P, Isaacs C, Pohlmann PR. Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. Breast Cancer Res Treat 168(1):35-41, 2018. e-Pub 2017. PMID: 29119354.
25. Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators. Surgical standards for management of the axilla in breast cancer clinical trials with pathological complete response endpoint. NPJ Breast Cancer 4:26, 2018. e-Pub 2018. PMID: 30131975.
26. Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 77(9):2488-2499, 2017. e-Pub 2017. PMID: 28249908.
27. Yan HP, Roberts LJ, Davies SS, Pohlmann P, Parl FF, Estes S, Maeng J, Parker B, Mernaugh R. Isolevuglandins as a gauge of lipid peroxidation in human tumors. Free Radic Biol Med 106:62-68, 2017. e-Pub 2017. PMID: 28189846.
28. Gao JJ, Tan M, Pohlmann PR, Swain SM. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens. Clin Breast Cancer 17(1):76-78, 2017. e-Pub 2016. PMID: 27692565.
29. Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann PR, Mohebtash M, Lee Y, Ottaviano Y, Mohapatra A, Lynce F, Brown R, Mete M, Swain SM. Video intervention increases participation of black breast cancer patients in therapeutic trials. NPJ Breast Cancer 3:36, 2017. e-Pub 2017. PMID: 28944289.
30. Mahajan AS, Sugita BM, Duttargi AN, Saenz F, Krawczyk E, McCutcheon JN, Fonseca AS, Kallakury B, Pohlmann P, Gusev Y, Cavalli LR. Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors. PLoS One 12(10):e0186190, 2017. e-Pub 2017. PMID: 29049316.
31. Falcetta FS, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT, Rosa DD. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev 11:CD005342, 2016. e-Pub 2016. PMID: 27873308.
32. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med 375(1):23-34, 2016. PMID: 27406347.
33. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med 375(1):11-22, 2016. PMID: 27406346.
34. Madhavan S, Aisner DL, Sheahan L, Sood N, Reddy S, Picora A, Wilhelm E, Volk J, Cusano D, Lucia K, Pohlmann PR, Marshall JL. Barriers to Implementation of Precision Medicine for Cancer Treatment in the U.S. Healthcare System. The Journal of Precision Medicine:48-56, 2016.
35. Shah AT, Demory Beckler M, Walsh AJ, Jones WP, Pohlmann PR, Skala MC. Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma. PLoS One 9(3):e90746, 2014. e-Pub 2014. PMID: 24595244.
36. Grothey A and Pohlmann PR. Expert Point of View: Three Molecular Subtypes of Colorectal Cancer Identified. The ASCO Post 4(6), 2013.
37. Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev(6):CD005342, 2012. e-Pub 2012. PMID: 22696349.
38. Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, Aulino J, Puzanov I, Murphy B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck 33(12):1804-8, 2011. e-Pub 2010. PMID: 20652976.
39. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 5(9):e12702, 2010. e-Pub 2010. PMID: 20856931.
40. Rosa DD, Medeiros LR, Edelweiss MI, Bozzetti MC, Pohlmann PR, Stein AT, Dickinson HO. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev(3):CD005342, 2009. e-Pub 2009. PMID: 19588370.
41. Savani BN, Pohlmann PR, Jagasia M, Chinratanalab W, Kassim A, Engelhardt B, Greer J, Schuening F, Goodman S. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?. Blood 113(24):6263-4, 2009. PMID: 19520823.
42. Pohlmann PR, Mernaugh RL, Goff LW. Chemotherapy and immunotherapy in metastatic colorectal cancer. N Engl J Med 360(20):2134; author reply 2135-6, 2009. PMID: 19439750.
43. Caleffi M, Ribeiro RA, Duarte Filho DL, Ashton-Prolla P, Bedin AJ, Skonieski GP, Zignani JM, Giacomazzi J, Franco LR, Graudenz M, Pohlmann P, Fernandes JG, Kivitz P, Weber B. A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort). BMC Public Health 9:83, 2009. e-Pub 2009. PMID: 19284670.
44. Menke CH, Pohlmann PR, Backes A, Cericatto R, Oliveira M, Bittelbrunn A, Schwartsmann G. Tumor size as a surrogate end point for the detection of early breast cancer: a 30-year (1972-2002), single-center experience in southern Brazil. Breast J 13(5):448-56, 2007. PMID: 17760665.
45. Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancella A, Pereira AS, Richter M, Souza F, da Rocha AB, Souza FH, Pohlmann P, De Nucci G. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 24(5):403-12, 2006. PMID: 16505950.
46. Toebak MJ, Pohlmann PR, Sampat-Sardjoepersad SC, von Blomberg BM, Bruynzeel DP, Scheper RJ, Rustemeyer T, Gibbs S. CXCL8 secretion by dendritic cells predicts contact allergens from irritants. Toxicol In Vitro 20(1):117-24, 2006. e-Pub 2005. PMID: 16099135.
47. Middelburg R, de Haas RR, Dekker H, Kerkhoven RM, Pohlmann PR, Fuentes-Alburo A, Mohar A, Pinedo HM, Lankelma J. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 11(5):1863-9, 2005. PMID: 15756011.
48. Medeiros LR, Rosa DD, Edelweiss MI, Stein AT, Bozzetti MC, Zelmanowicz A, Pohlmann PR, Meurer L, Carballo MT. Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. Int J Gynecol Cancer 15(2):192-202, 2005. PMID: 15823099.
49. Rosa DD, Medeiros LR, Bozzetti MC, Edelweiss MI, Pohlmann PR, Stein, AT. Adjuvant chemotherapy for early-stage cervix cancer (Protocol). The Cochrane Database of Systematic Reviews 3:1-8, 2005.
50. Medeiros LR, Rosa DD, Bozzetti MC, Edelweiss MI, Stein AT, Pohlmann PR, Zelmanowicz AM, Ethur AB, Zanini RR. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer (Protocol). The Cochrane Database of Systematic Reviews 3:1-12, 2005.
51. Pohlmann PR, Suchil Bernal L, Fuentes Alburo A, Buter J, Gallardo Rincon D, Mohar A, Mayordomo JI, van der Hoeven JJM, van der Wall E, de Gruijl T, Pinedo HM. Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: Clinical and biological concepts. Rev Oncol (Clinical and Translational Oncology) 6(3):130-9, 2004.
52. Pinedo HM, Buter J, Luykx-de Bakker SA, Pohlmann PR, van Hensbergen Y, Heideman DA, van Diest PJ, de Gruijl TD, van der Wall E. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur J Cancer 39(8):1061-7, 2003. PMID: 12736104.
53. Pohlmann P, DiLeone LP, Cancella AI, Caldas AP, Dal Lago L, Campos O, Monego E, Rivoire W, Schwartsmann G. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25(5):496-501, 2002. PMID: 12393992.
54. Venegas LF, Pohlmann PR, Balbinot AL, Schuck E, Oliveira CTM, Frank KJ, Dillemburg CF, da Costa MS, Rivero LF, Putten ACK. Primary splenic angiosarcoma: case report and literature review. Rev Bras Cancerol 44(1):51-6, 1998.
55. Schwartsmann G, Mans DR, Menke CH, Xavier N, Caleffi M, Ferreira Filho AF, Schunemann H, Kalakun L, Koya R, Pohlman P, Venegas LF. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Oncology (Williston Park) 11(4 Suppl 3):24-9, 1997. PMID: 9144687.
56. Dietz J, Prolla JC, Pohlmann PR, Loss JF, Da Costa LA, Daudt AW, Grassi P, Achutti AC. [Mortality from uterine cervix cancer in Rio Grande do Sul]. Rev Assoc Med Bras (1992) 39(3):146-50, 1993. PMID: 8281197.
57. Daudt AW, Prolla JC, Dietz J, Grassi PR, Arnt CA, Loss JF, Costa LA, Pohlmann PR. Tobacco-related diseases: a 21-year study (1970-1990) of the mortality rate in the state of Rio Grande do Sul, Brazil. The Journal of Smoking-Related Disorders 4(3):155-63, 1993.
58. Loss JF, Barrionuevo AA, Pohlmann PR. Estudantes de Medicina: II. Informações e medo da SIDA. Revista de Medicina ATM 13:65-9, 1992.
59. Barrionuevo AA, Pohlmann PR, Loss JF. Estudantes de Medicina: I. Aprendizado dos procedimentos básicos fundamentais à medicina. Revista de Medicina ATM 13:59-4, 1992.
60. Pohlmann PR, Loss JF, Marzola B, Polanczyk CA, Zampese MS, Kronfeld M. Sarcoma de Kaposi e SIDA - HCPA: avaliação da sobrevida. Revista de Medicina ATM 13:76-80, 1992.
61. Loss JF, Pohlmann PR. Aspectos Emocionais da Síndrome da Imunodeficiência Adquirida em Pediatria. Revista de Medicina ATM 13:164-8, 1992.
62. Pohlmann PR, Loss JF, Barrionuevo AA. Estudantes de Medicina: III. O que sabem sobre a organização do sistema de saúde?. Revista de Medicina ATM 13:70-5, 1992.
63. Pohlmann PR, Loss JF, Flores C, Bolzzoni A, Duncan BB, Zimmer PM. [Smoking in Porto Alegre: prevalence and the role of health professionals in its prevention]. AMB Rev Assoc Med Bras 37(1):8-14, 1991. PMID: 1658870.

Invited Articles

1. Xiao J, Pohlmann PR, Isaacs C, Weinberg BA, He AR, Schlegel R, Agarwal S. Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis. Biomedicines 30(9):1111, 2021. PMID: 34572297.
2. Gallanis GT, Pericas RI, Riegel AT, Pohlmann PR. An evaluation of palbociclib as a breast cancer treatment option: a current update. Expert Opin Pharmacother 22(3):281-90, 2021. e-Pub 2020. PMID: 33198527.
3. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 15(24):7479-91, 2009. PMID: 20008848.

Editorials

1. Pohlmann PR, Isaacs C. Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. J Natl Cancer Inst 110(1):3-5, 2018. PMID: 28922782.

Abstracts

1. Pohlmann PR. Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: HER2-mutated breast cancer cohort (Trial in Progress). 2021 ESMO Breast Cancer Virtual Congress, 2021.
2. Xiao J, Kassner JD, Stanton K, Schlegel R, Pohlmann PR, Agarwal S. A robust method for expanding patient-derived circulating tumor cells ex vivo. Cancer Res-Proceedings: 2021 Annual American Association for Cancer Research (AACR) Meeting, 2021.
3. Sharma MR, Carvajal RD, Catenacci D, Emens LA, Hanna GJ, Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Heeke AL, Wang D, Garbo L, Manda S, Sachdev J, Ackerman SE, LeBlanc H, Dornan D, Kowanetz M, Alonso MN, Husain A, Perez EA, Dumbrava EI. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors. Cancer Res-Proceedings: 2021 Annual American Association for Cancer Research (AACR) Meeting, 2021.
4. Piha-Paul S, Bendell JC, Tolcher A, Shroff R, Pohlmann PR, Hurvitz SA, Krishnamurthy A, Pandya N, Olwill SA, Zettl M, Aviano K, Mar L, Jolicoeur P, Kastresana AM, Schlosser C, Bruns I, Bexon A amd Ku GY. Abstract CT017: Clinical and biomarker activity of PRS-343, a bispecific fusion protein targeting 4-1BB and HER2, from a phase 1 study in patients with advanced solid tumors (Study PRS-343-PCS_04_16). Cancer Res-Proceedings: 2021 Annual American Association for Cancer Research (AACR) Meeting, 2021.
5. Vidula N, Nanda R, Miller KD, Emens LA, Pohlmann PR, Abramson VG, Park BH, Liu MC, Goga A, Rugo HS. Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044. 2021 Annual American Society of Clinical Oncology (ASCO) Meeting, 2021.
6. Stinchcombe T, Monk BJ, Okines AFC, Pohlmann PR, Yu EY, Bekaii-Saab TS, Nakamura Y, O'Malley DM, Kang V, Walker LN, Reck M. Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress). 2021 Annual American Society of Clinical Oncology (ASCO) Meeting, 2021.
7. Stinchcombe T, Monk BJ, Okines AFC, Pohlmann PR, Yu EY, Bekaii-Saab TS, Nakamura Y, O'Malley DM, Kang V, Walker LN, Reck M. SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress). J Clin Oncol-Proceedings: 2021 Annual American Society of Clinical Oncology (ASCO) Meeting 39(15), 2021.
8. Vidula N, Nanda R, Miller KD, Emens LA, Pohlmann PR, Abramson VG, Park BH, Liu MC, Goga A, Rugo HS. Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044. J Clin Oncol-Proceedings: 2021 Annual American Society of Clinical Oncology (ASCO) Meeting 39(15), 2021.
9. Giri U, Xiu J, Karadimitriou T, Castanon S, Ademuyiwa F, Pohlmann PR, Oeid E, Sachdev J, Krill-Jackson E, Simon M, Tan A, Denduluri N, Schwartzberg L, Korn N, and Torres ETR. Molecular evaluation of immunogenicity and genomic alterations in invasive lobular breast cancer. Cancer Res-Proceedings: 2020 Annual San Antonio Breast Cancer Symposium (SABCS) 81(4), 2021.
10. Castanon S, Flores D, Xiu J, Pohlmann PR, Ademuyiwa F, Obeid E, Sachdev J, Simon M, Jackson EK, Schwartzberg L, Tan AR, Denduluri N, Korn WM and Torres ETR. The immune microenvironment of liver metastasis as a guide for immunotherapeutic potential in breast cancer. Cancer Res-Proceedings: 2020 Annual San Antonio Breast Cancer Symposium (SABCS) 81(4), 2021.
11. Vidula N, Nanda R, Miller K, Pohlmann PR, Abramson V, Emens LA, Park BH, Liu MC, Goga A, Rugo HS. Translational breast cancer research consortium 044 trial: Randomized phase 2 study of pembrolizumab and carboplatin versus carboplatin alone for chest wall recurrence of breast cancer. Cancer Res-Proceedings: 2020 Annual San Antonio Breast Cancer Symposium (SABCS) 81(4), 2021.
12. Dumbrava EI, Sharma MR, Carvajal RD, Catenacci D, Emens LA, Gadgeel SM, Hanna GJ, Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Tan AR, Ackerman SE, LeBlanc H, Dornan D, Kowanetz M, Alonso MN and Perez EA. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. Cancer Res-Proceedings: 2020 Annual San Antonio Breast Cancer Symposium (SABCS) 81(4), 2021.
13. Hamilton E, Reinisch M, Loi S, Okines A, Pohlmann PR, Brix EH, Bourgeois H, Yeo B, Aylesworth C, Cobleigh M, Goncalves A, Moroose R, Tkaczuk KHR, Tsai M, Simmons C, Andersson M, Soliman H, Cairo M, Carey LA, Cameron D, Ramos J, Feng W, and Oliveira M. Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status. 2020 Annual San Antonio Breast Cancer Symposium (SABCS), 2020.
14. Dumbrava EI, Sharma MR, Carvajal RD, Catenacci D, Emens LA, Gadgeel SM, Hanna GJ, Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Tan AR, Ackerman SE, LeBlanc H, Dornan D, Kowanetz M, Alonso MN and Perez EA. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. 2020 Annual San Antonio Breast Cancer Symposium (SABCS), 2020.
15. Vidula N, Nanda R, Miller K, Pohlmann PR, Abramson V, Emens LA, Park BH, Liu MC, Goga A, Rugo HS. Translational breast cancer research consortium 044 trial: Randomized phase 2 study of pembrolizumab and carboplatin versus carboplatin alone for chest wall recurrence of breast cancer. 2021 Annual San Antonio Breast Cancer Symposium (SABCS), 2020.
16. Castanon S, Flores D, Xiu J, Pohlmann PR, Ademuyiwa F, Obeid E, Sachdev J, Simon M, Jackson EK, Schwartzberg L, Tan AR, Denduluri N, Korn WM and Torres ETR. The immune microenvironment of liver metastasis as a guide for immunotherapeutic potential in breast cancer. 2020 Annual San Antonio Breast Cancer Symposium (SABCS), 2020.
17. Giri U, Xiu J, Karadimitriou T, Castanon S, Ademuyiwa F, Pohlmann PR, Oeid E, Sachdev J, Krill-Jackson E, Simon M, Tan A, Denduluri N, Schwartzberg L, Korn N, and Torres ETR. Molecular evaluation of immunogenicity and genomic alterations in invasive lobular breast cancer. 2020 Annual San Antonio Breast Cancer Symposium (SABCS), 2020.
18. Hamilton E, Reinisch M, Loi S, Okines A, Pohlmann PR, Brix EH, Bourgeois H, Yeo B, Aylesworth C, Cobleigh M, Goncalves A, Moroose R, Tkaczuk KHR, Tsai M, Simmons C, Andersson M, Soliman H, Cairo M, Carey LA, Cameron D, Ramos J, Feng W, and Oliveira M. Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): outcomes by hormone receptor status. Cancer Res-Proceedings: 2020 Annual San Antonio Breast Cancer Symposium (SABCS) 81(4), 2020.
19. Murthy R, O’Brien B, Berry D, Navin N, Johnson J, Gule-Monroe M, Leone J, Specht J, Melisko M, Morikawa A, Storniolo A, Brufsky A, Pohlmann P, Park D, Park B, Krop I, Lin N, Rimawi M, Wolff A, Forero-Torres A and Stringer-Reasor E. A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2-positive breast cancer. 2020 Annual Society for Neuro-Oncology (SNO) Meeting, 2020.
20. Khoury K, Barac A, Lynce F, Geng X, Dang CT, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer PM, Warren RD, Srichai MB, Hofmeyer M, Asch FM, Tan MT, Isaacs C and Swain SM. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function. 2020 Annual American Society of Clinical Oncology (ASCO) Virtual Scientific Program, 2020.
21. Lander EM, Lehmann BD, Shah PD, Dees EC, Ballinger TJ, Pohlmann PR, Santa-Maria CA, Shyr Y, Mayer IA, Park BH, Pietenpol JA and Abramson VG. A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC). 2020 Annual American Society of Clinical Oncology (ASCO) Virtual Scientific Program, 2020.
22. Vidula N, Nanda R, Miller K, Pohlmann PR, Abramson VG, Emens LA, Park BH, Liu NC, Goga A and Rugo HS. Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial. 2020 Annual American Society of Clinical Oncology (ASCO) Virtual Scientific Program, 2020.
23. Lander EM, Lehmann BD, Shah PD, Dees EC, Ballinger TJ, Pohlmann PR, Santa-Maria CA, Shyr Y, Mayer IA, Park BH, Pietenpol JA and Abramson VG. A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol-Proceedings: 2020 Annual American Society of Clinical Oncology (ASCO) Meeting 38(15), 2020.
24. Khoury K, Barac A, Lynce F, Geng X, Dang CT, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer PM, Warren RD, Srichai MB, Hofmeyer M, Asch FM, Tan MT, Isaacs C and Swain SM. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function. J Clin Oncol-Proceedings: 2020 Annual American Society of Clinical Oncology (ASCO) Meeting 38(15), 2020.
25. Vidula N, Nanda R, Miller K, Pohlmann PR, Abramson VG, Emens LA, Park BH, Liu NC, Goga A and Rugo HS. Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial. J Clin Oncol-Proceedings: 2020 Annual American Society of Clinical Oncology (ASCO) Meeting 38(15), 2020.
26. Piha-Paul S, Bendel J, Tolcher A, Hurvitz S, Patnaik A, Shroff R, Pohlmann P, Zettl M, Hahn N, Krishnamurthy A, Duerr M, Mei J, Aviano K, Yusuf R, Matis L, Olwill S, Bruns I and Ku G. O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies. JITC 8(1), 2020.
27. Vidula N, Nanda R, Miller K, Abramson V, Pohlmann P, Brufsky A, Park B, Liu M, Goga A, and Rugo HS. Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial. Cancer Res-Proceedings: 2019 Annual San Antonio Breast Cancer Symposium (SABCS) 80(4), 2020.
28. Heeke, AL, Pishvaian M, Wang H, Cohen A, Schlom J, Donahue R, Jochems C, Gatti-Mays M, Pohlmann P, Tan A, Isaacs C and Lynce F. A trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: The TALAVE study. Cancer Res-Proceedings: 2019 Annual San Antonio Breast Cancer Symposium (SABCS) 80(4), 2020.
29. Murthy RK, O'Brien BJ, Hess KR, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Park DM, Park BH, Krop I, Lin NU, Wolff A, Forerro-Torres A and Stringer-Reasor E. TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer. Cancer Res-Proceedings: 2019 Annual San Antonio Breast Cancer Symposium (SABCS) 80(4), 2020.
30. Lynce F, Zhuo R, Blackburn M, Gallagher C, Hahn O, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann P, Dilawari A, Tiwari S, Chitalia A, Warren R, Tan M, Shajahan-Haq A, and Isaacs C. Safety of palbociclib in African American women with hormone receptor positive HER2 negative advanced breast cancer and benign ethnic neutropenia: PALINA study. Cancer Res-Proceedings: 2019 Annual San Antonio Breast Cancer Symposium (SABCS) 80(4), 2020.
31. Khoury K, Tan A, Elliott A, Xiu J, Gatalica Z, Heeke AL, Isaacs C, Pohlmann PR, Schwartzberg LS, Simon M, Korn MW, Swain SM and Lynce F. Prevalence of phosphatidylinositol-3-kinase (PI3K) pathway alterations and co-alteration of other markers in breast cancer. Cancer Res-Proceedings: 2019 Annual San Antonio Breast Cancer Symposium (SABCS) 80(4), 2020.
32. Assad H, Hart I, Purrington K, Xiu J, Pohlmann PR, Swain S, Vidal G and Simon M. Somatic genomic profiles of breast tumors differ by BRCA1 and BRCA2 variants of unknown significance status. Cancer Res-Proceedings: 2019 Annual San Antonio Breast Cancer Symposium (SABCS) 80(4), 2020.
33. Vidula N, Nanda R, Miller K, Abramson V, Pohlmann P, Brufsky A, Park B, Liu M, Goga A, and Rugo HS. Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019.
34. Lynce F, Zhuo R, Blackburn M, Gallagher C, Hahn O, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann P, Dilawari A, Tiwari S, Chitalia A, Warren R, Tan M, Shajahan-Haq A, and Isaacs C. Safety of palbociclib in African American women with hormone receptor positive HER2 negative advanced breast cancer and benign ethnic neutropenia: PALINA study. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019.
35. Murthy RK, O'Brien BJ, Hess KR, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Park DM, Park BH, Krop I, Lin NU, Wolff A, Forerro-Torres A, and Stringer-Reasor E. TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019.
36. Khoury K, Tan A, Elliott A, Xiu J, Gatalica Z, Heeke AL, Isaacs C, Pohlmann PR, Schwartzberg LS, Simon M, Korn MW, Swain SM and Lynce F. Prevalence of phosphatidylinositol-3-kinase (PI3K) pathway alterations and co-alteration of other markers in breast cancer. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019.
37. Pohlmann PR, Yau C, DeMichele A, Isaacs C, Boughey JC, Hylton N, Melisko ME, Perlmutter J, Rugo HS, Symmans W, I-SPY2 Trial Consortium, Berry DA, Esserman L. Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019.
38. Pohlmann PR, Yau C, DeMichele A, Isaacs C, Boughey JC, Hylton N, Melisko ME, Perlmutter J, Rugo HS, Symmans W, I-SPY2 Trial Consortium, Berry DA, Esserman L. Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019.
39. Assad H, Hart I, Purrington K, Xiu J, Pohlmann PR, Swain S, Vidal G and Simon M. Somatic genomic profiles of breast tumors differ by BRCA1 and BRCA2 variants of unknown significance status. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019.
40. Heeke, AL, Pishvaian M, Wang H, Cohen A, Schlom J, Donahue R, Jochems C, Gatti-Mays M, Pohlmann P, Tan A, Isaacs C and Lynce F. A trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: The TALAVE study. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019.
41. Wulfkuhle JD, Wolf DM, Yau C, Gallagher RI, Swigart LB, Hirst GL, Yee D, Pohlmann PR, Elias AD, Moulder SL, Tripathy D, DeMichele A, Esserman L, Berry DA, van 't Veer L, Petricoin E, I-SPY 2 Investigators. HER family protein expression and activation predict response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. 2019 Annual American Society of Clinical Oncology (ASCO) Meeting, 2019.
42. Heeke AL, Xiu J, Lynce F, Pohlmann PR, Vidal GA, Isaacs C, Swain SM, Schwartzberg LS, Tan AR. Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. 2019 Annual American Society of Clinical Society (ASCO) Meeting, 2019.
43. Khoury K, Feldman R, Pohlmann PR, Heeke AL, Gatalica Z, Veloso Y, Vidal GA, Schwartzberg LS, Swain SM, Isaacs C, Lynce F. Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC). J Clin Oncol, 2019.
44. Wulfkuhle JD, Wolf DM, Yau C, Gallagher RI, Swigart LB, Hirst GL, Yee D, Pohlmann PR, Elias AD, Moulder SL, Tripathy D, DeMichele A, Esserman L, Berry DA, van 't Veer L, Petricoin E, I-SPY 2 Investigators. HER family protein expression and activation predict response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. J Clin Oncol-Proceedings: 2019 Annual American Society of Clinical Oncology (ASCO) Meeting 37(15):3133, 2019.
45. Heeke AL, Xiu J, Lynce F, Pohlmann PR, Vidal GA, Isaacs C, Swain SM, Schwartzberg LS, Tan AR. Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. J Clin Oncol-Proceedings: 2019 Annual American Society of Clinical Oncology (ASCO) Meeting 37(15), 2019.
46. Khoury K, Isaacs C, Gatti-Mays ME, Donahue RN, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain SM, Pohlmann PR, Lynce F. Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study. Cancer Res-Proceedings: 2018 Annual San Antonio Breast Cancer Symposium (SABCS) 79(4), 2019.
47. Sengupta S, Sevigny CM, Jones BC, Jin L, Pohlmann PR, Calrke R. Targeting PFKFB3 enzyme induces cell death via reactive oxygen species-mediated toxicity in endocrine therapy-resistant breast cancers. Cancer Res-Proceedings: 2018 Annual San Antonio Breast Cancer Symposium (SABCS) 79(4), 2019.
48. Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson V, Rugo HS. A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. Cancer Res-Proceedings: 2018 Annual San Antonio Breast Cancer Symposium (SABCS) 79(4), 2019.
49. Sengupta S, Sevigny CM, Jones BC, Jin L, Pohlmann PR, Calrke R. Targeting PFKFB3 enzyme induces cell death via reactive oxygen species-mediated toxicity in endocrine therapy-resistant breast cancers. 2018 Annual San Antonio Breast Cancer Symposium (SABCS), 2018.
50. Wolf DM, Yau C, Wulfkuhle J, Petricoin E, Campbell M, Brown-Swigart L, Hirst G, Asare S, Zhu Z, Lee EP, Delson A, Pohlmann P, I-SPY 2 TRIAL Consortium, Hylton N, Liu MC, Symmans F, DeMichele A, Yee D, Berry D, Esserman L, van 't Veer L. Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ~1000 patients across 10 arms of the I-SPY 2 TRIAL. 2018 Annual San Antonio Breast Cancer Symposium (SABCS), 2018.
51. Khoury K, Isaacs C, Gatti-Mays ME, Donahue RN, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain SM, Pohlmann PR, Lynce F. Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study. 2018 Annual San Antonio Breast Cancer Symposium (SABCS), 2018.
52. Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson V, Rugo HS. A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. 2018 Annual San Antonio Breast Cancer Symposium (SABCS), 2018.
53. Pohlmann P, Diamond J, Hamilton E, Tolaney SM, Powderly J, Molinero L, Zhang W, Iizuka K, Foster P, Funke R, Adams S. Atezolizumab (atezo) plus nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph 1b trial. Cancer Res-Proceedings: 2018 Annual American Association for Cancer Research (AACR) Meeting, 2018.
54. • Sengupta S, Liu X, Sevigny CM, Jin L, Pohlmann PR, Clarke R. Targeting glycolysis enzyme, PFKFB3, in endocrine therapy resistant breast cancers. Cancer Res-Proceedings: 2018 Annual American Association for Cancer Research (AACR) Meeting 78(13), 2018.
55. Lynce F, Barac A, Geng X, Dang CT, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer PM, Warren RD, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq AN, Tan MT, Isaacs C, Swain SM. SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function. 2018 Annual American Society of Clinical Oncology (ASCO ) Meeting, 2018.
56. Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson VG, Rugo HS. A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. 2018 Annual American Society of Clinical Oncology (ASCO ) Meeting, 2018.
57. • Madhavan S, Blais EM, Bender RJ, Chung VM, Hendifar AE, Mikhail S, Lowery MA, Sohal D, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Petricoin E, Halverson DC, Pishvaian MJ. A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers. J Clin Oncol 36(15), 2018.
58. Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson VG, Rugo HS. A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. J Clin Oncol-Proceedings: 2018 Annual American Society of Clinical Oncology (ASCO) Meeting 36(15), 2018.
59. Lynce F, Barac A, Geng X, Dang CT, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer PM, Warren RD, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq AN, Tan MT, Isaacs C, Swain SM. SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function. J Clin Oncol-Proceedings: 2018 Annual American Society of Clinical Oncology (ASCO) Meeting 36(15), 2018.
60. Sengupta S, Sevigny CM, Liu X, Jin L, Pohlmann PR and Clarke R. Targeting glycolysis enzyme, PFKFB3, in endocrine therapy resistant breast cancers. 2018 Annual American Association for Cancer Research (AACR) Meeting, 2018.
61. Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney 5M, Chang CW, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R and Powderly J. Atezolizumab (atezo) plus nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph 1b trial. 2018 Annual American Association for Cancer Research (AACR) Meeting, 2018.
62. Lynce F, Xiu J, Obeid E. Tan AR, Gatalica Z, Isaacs C, Pohlmann PR. Tumor mutational load in gynecological and breast cancer. J Clin Oncol-Proceedings: 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 35(7), 2018.
63. Vidula N, Goga A, Krummel M, Hwang J, Liu M, Park BH, Nanda R, Pohlmann P, Storniolo AM, Van Poznak C, Brufsky A, Abramson V, Wolff A, Rugo HS. TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease. Cancer Res-Proceedings: 2017 Annual San Antonio Breast Cancer Symposium (SABCS) 78(4), 2018.
64. Vidula N, Goga A, Krummel M, Hwang J, Liu M, Park BH, Nanda R, Pohlmann P, Storniolo AM, Van Poznak C, Brufsky A, Abramson V, Wolff A, Rugo HS. TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease. 2017 Annual San Antonio Breast Cancer Symposium (SABCS), 2017.
65. ElChaarani B, Stires H, Pohlmann PR, Riggins R. Pre-clinical analysis of the CDK4/6 inhibitor palbociclib in HER2-positive breast cancer. J Clin Oncol 356(15). e-Pub 2017.
66. Caleffi M, Burchardt NA, Scapin HP, Crivelatti I, Gomes CS, Gomes AL and Pohlmann PR. Patient-reported outcomes in metastatic breast cancer: QoL, needs, and expectations of survivors. J Clin Oncol-Proceedings: 2017 American Society of Clinical Oncology (ASCO) Cancer Survivorship Symposium 35(5), 2017.
67. Pohlmann PR, van Cruijsen H, Stam AGM, Lougheed SM, van den Eertwegh AJM, Hoekman K, Scheper R, Buter J, van der Hoeven JJM, van der Wall E, Pinedo HM, de Gruijl TD. Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study. Cancer Res-Proceedings: 2017 Annual San Antonio Breast Cancer Symposium (SABCS) 77(4), 2017.
68. Lynce F, Xiu J, Nunes MR, Swain SM, Gatalica Z, Isaacs C and Pohlmann P. Racial differences in the molecular landscape of breast cancer. Cancer Res-Proceedings: 2016 Annual San Antonio Breast Cancer Symposium (SABCS) 77(4), 2017.
69. Tan A, Feldman R, Pohlmann PR, Lynce F, Swain S, Nunes MR, Gatalica Z, Ghazalpour A, Swensen J, Vidal G, Obeid E, Vacirca J, Isaacs C, Schwartzberg L. ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors. Cancer Res-Proceedings: 2016 Annual San Antonio Breast Cancer Symposium (SABCS) 77(4), 2017.
70. Swain S, Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann PR, Mohebtash M, Ottaviano Y, Mohapatra A, Lynce F, Mete M. Increasing participation in research - breast cancer (Inspire-BrC). Cancer Res-Proceedings: 2016 Annual San Antonio Breast Cancer Symposium (SABCS) 77(4), 2017.
71. Lynce F, Xiu J, Obeid E, Tan AR, Gatalica Z, Isaacs C, Pohlmann PR. Tumor mutational load in gynecological and breast cancer. 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, 2017.
72. Caleffi M, Burchardt NA, Scapin HP, Crivelatti I, Gomes CS, Gomes AL and Pohlmann PR. Patient-reported outcomes in metastatic breast cancer: QoL, needs, and expectations of survivors. 2017 American Society of Clinical Oncology (ASCO) Cancer Survivorship Symposium, 2017.
73. Pohlmann PR, H van Cruijsen, AGM Stam, SM Lougheed, AJM van den Eertwegh, K Hoekman, R Scheper, J Buter, JJM van der Hoeven, E van der Wall, HM Pinedo, and TD de Gruijl. Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study. 2016 Annual San Antonio Breast Cancer Symposium (SABCS), 2016.
74. Lynce F, Xiu J, Nunes MR, Swain SM, Gatalica Z, Isaacs C and Pohlmann P. Racial differences in the molecular landscape of breast cancer. 2016 Annual San Antonio Breast Cancer Symposium (SABCS), 2016.
75. Tan A, Feldman R, Pohlmann P, Lynce F, Swain S, Nunes MR, Gatalica Z, Ghazalpour A, Swensen J, Vidal G, Obeid E, Vacirca J, Isaacs C, and Schwartzberg L. ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors. 2016 Annual San Antonio Breast Cancer Symposium (SABCS), 2016.
76. Swain S, Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann PR, Mohebtash M, Ottaviano Y, Mohapatra A, Lynce F, Mete M. Increasing participation in research - breast cancer (Inspire-BrC). 2016 Annual San Antonio Breast Cancer Symposium (SABCS), 2016.
77. Adams S, Diamond JR, Hamilton EP, Pohlmann PR, Tolaney SM, Molinero L, He X, Waterkamp D, Funke RP, Powderly JD. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). 2016 Annual American Society of Clinical Oncology (ASCO) Meeting, 2016.
78. Pishvaian MJ, Wang H, Smaglo BG, Gao J, Redmond LME, Permaul ECA, Sen S, McCarthy DL, Kallakury B, Liu SV, He AR, Hwang JJ, Swain SM, Marshall J and Pohlmann PR. A Phase I Study of the CDK4/6 Inhibitor, Palbociclib plus 5-Fluorouracil (5FU) in Patients with Advanced Solid Tumor Malignancies (NCT01522989). 2016 Annual American Society of Clinical Oncology (ASCO) Meeting, 2016.
79. Adams S, Diamond J, Hamilton E, Pohlmann PR, Tolaney S, Molinero L, He X, Waterkamp D, Funke R, Powderly J. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol-Proceedings: 2016 Annual American Society of Clinical Oncology (ASCO) Meeting 34(15), 2016.
80. Pishvaian MJ, Wang H, Smaglo BG, Gao J, Macke L, Redmond E, Permaul ECA, Sen S, McCarthy DL, Kallakury B, Liu SV, He AR, Hwang JJ, Swain SM, Marshall J, Pohlmann PR. A Phase I Study of the CDK4/6 Inhibitor, Palbociclib plus 5-Fluorouracil (5FU) in Patients with Advanced Solid Tumor Malignancies (NCT01522989). J Clin Oncol-Proceedings: 2016 Annual American Society of Clinical Oncology (ASCO) Meeting 34(15), 2016.
81. Adams S, Diamond J, Hamilton E, Pohlmann P, Tolaney S, Molinero L, Zou W, Liu B, Waterkamp D, Funke R, and Powderly J. Safety and clinical activity of atezolizumab (anti-PDL1 MAb) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. 2015 Annual San Antonio Breast Cancer Symposium (SABCS), 2015.
82. Xiu J, Reddy SK, and Pohlmann PR. Tumor profiling of 1168 geriatric breast tumors. 2015 Annual American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, 2015.
83. Redman RA, Pohlmann PR, Kurman MR, Tapolsky G, Chesney J. PFK-158, first-in-man and first-in-class inhibitor of PFKFB3/ glycolysis: A phase I, dose escalation, multi-center study in patients with advanced solid malignancies. Cancer Res-Proceedings: 2015 Annual American Association for Cancer Research (AACR) Meeting 75(15), 2015.
84. Redman RA, Pohlmann PR, Kurman MR, Tapolsky G, Chesney J. A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis. J Clin Oncol -Proceedings: 2015 Annual Gastrointestinal Cancers (ASCO GI) Symposium 33(3), 2015.
85. Shah A, Walsh A, Pohlmann PR and Skala M. Quantitative Autofluorescence Imaging Measures Early Response to Head and Neck Cancer Treatment In Vivo. Optics 2014, OSA Technical Digest (online) (Optical Society of America, 2014), 2014.
86. Johnson MD, Haddad BR, Clarke R, Pohlmann PR, Isaacs C. Do conditionally reprogrammed cell cultures represent the tumors they have been isolated from with high fidelity?. J Clin Oncol-Proceedings: 2014 Annual American Society of Clinical Oncology (ASCO) Meeting 32(15), 2014.
87. Pohlmann PR, Simmons S, Baker J, Baucom L, Mernaugh R, Dawson E. Detection of anti-drug antibodies (ADAs) reactive with trastuzumab in HER2-positive breast cancer patients treated with trastuzumab. J Clin Oncol 32(15), 2014.
88. Pohlmann PR. Routine multiplexed mutational analysis of colorectal cancers – the updated Vanderbilt experience. Meharry Medical College/Vanderbilt Ingram Cancer Center/Tennessee State University Cancer Partnership 12th Annual Cancer Retreat: The Interface Between Cancer and the Immune System, 2013.
89. Pohlmann PR , Miller TW, Blum DL, Pareh D, Yan H, Sutton CR, Dugger TL, Salazar LG, Wu W, Reyzer ML, Disis ML, Mernaugh R, Arteaga CL. Trastuzumab-reactive antibodies (TR-abs) in serum and trastuzumab (Tzb) benefit prediction in patients with HER2-overexpressing breast cancer. 2012 Markers in Cancer (ASCO, EORTC, NCI), 2012.
90. Pohlmann PR, Miller TW, Blum DL, Parek D, Yan H, Sutton CR, Dugger T, Salazar LG, Wu W, Reyzer ML, Disis ML, Mernaugh R, Arteaga CL. Trastuzumab-reactive antibodies (TR-abs) in serum and trastuzumab (Tzb) benefit prediction in patients with HER2-overexpressing breast cancer. J Clin Oncol-Proceedings:2012 Markers in Cancer (ASCO, EORTC, NCI) 30(30), 2012.
91. Pohlmann P, Miller T, Blum D, Parek D, Yan H, Rinehart C, Dugger T, Diss M, Mernaugh R, Artega C. Anti-Trastuzumab Antibodies are Associated with Longer Progression Free Survival in Patients Treated with Trastuzumab. 2010 Annual San Antonio Breast Cancer Symposium (SABCS), 2010.
92. Pohlmann PR. An active immune network is a surrogate marker for early tumor response to trastuzumab in a pre-clinical model of breast cancer. 2006 Annual San Antonio Breast Cancer Symposium (SABCS), 2006.
93. • Caleffi M, Duarte Filho D, Skoniesky G, Bedin Jr A, Zignani JM, Antunes LP, Dias EC, Ashton-Prolla P, Weber B, Kivitz P, Graudenz MS, Pohlmann PR. The controversy of annual mammographic screening (AMS) for 40 to 69y-o women of Brazilian cohort of 10.000 underserved women. 2005 Annual San Antonio Breast Cancer Symposium (SABCS), 2005.
94. Caleffi M, Ashton-Prolla P, Weber B, Zignani JM, Dias EC, Antues LP, Junior AB, Lisboa E, Graudenz M, Pohlmann PR and Filho DD. Breast cancer screening in 10,000 women of an underserved population in South Brazil: The NMAMAPOA Cohort. 2005 Annual American Society of Clinical Oncology (ASCO) Meeting, 2005.
95. Caleffi M, Ashton-Prolla P, Weber B, Zignani JM, Dias EC, Antunes LP, Bedin Jr A, Lisboa E, Graudenz M, Pohlmann PR, Duarte Filho D. Breast cancer screening in 10,000 women of an underserved population in South Brazil: The NMAMAPOA Cohort. J Clin Oncol-Proceedings: 2005 Annual American Society of Clinical Oncology (ASCO) Meeting 23(16), 2005.
96. Pohlmann PR. Breast cancer epidemiology and annual mammographic screening (AMS) in 10,000 women of an underserved population in South Brazil. 2004 Annual San Antonio Breast Cancer Symposium (SABCS), 2004.
97. Gibbs S, Toebak M, Pohlmann PR, Blomberg B, Scheper R, Rustemeyer T and Bruynzeel D. FS13.7 CXCL8: a potential novel marker in predicting contact sensitisers. Contact Dermatitis 50(3):174, 2004.
98. Toebak MJ, Pohlmann PR, von Blomberg BME, Scheper RJ, Rustemeyer T and Gibbs S. Chemokineproductie door `monocyte-derived´ dendritische cellen n blootstelling aan allergenen en irritanten. Nederlands Trjdsclinift Voor Dermatologie Venereologie 14(1):60, 2004.
99. Xavier N, Pohlmann PR, Menke CH, Biazus JV, Uchoa D, Detanico MF, Schwartsmann G, Cavalheiro JA, Cericatto R, Rabin EG, Bittelbrunn AC. Sentinel Lymph Node Predictors for Metastasis in Patients with T1C and T2 Breast Cancer. 13th International Congress on Senology (Breast Diseases), 2004.
100. Toebak MJ, Pohlmann PR, von Blomberg BME, Bruynzeel DP, Scheper RJ, Rustemeyer T and Gibbs S. Unique potential of the contact sensitizer nickel to mature monocyte-derived dendritic cells. Dutch Society for Immunology. Dutch Society for Immunology, Winter Meeting, 2003.
101. Toebak MJ, Masterson AJ, Pohlmann PR et al. MUTZ-3 cellijn is vergelijkbaar met monocyte-derived dendritische cellen in het orderscheiden van allergenen en irritanten. Nederlands Tijdschrift Voor Dermatologie Venereologie, Holanda 13:64, 2003.
102. Nonnenmacher B, Perez LS, Bozzetti MC, Pohlmann PR, Cancian FS, Zettler CG, Mielzynska-Lohnas I, Dores GB. Prevalence of ASCUS and its relationship with HPV-DNA and cervical lesion. 20th International Papillomavirus Conference:228, 2002.
103. Bozzetti MC, Pohlmann PR, Loss JF, Breitenbach V, Cancian FS, Zettler CG, Mielzynska-Lohnas I, Putten AC, Schwartsmann G, Dores GB, Nonnenmacher B. Hybrid Capture for HPV DNA Testing in Cervical Cancer Screening. 20th International Papillomavirus Conference:239, 2002.
104. Toebak MJ, Masterson AJ, Pohlmann PR, Stoof T, von Blomberg BME, Bruynzeel DP, Scheper RJ, Rustemeyer T and Gibbs S. MUTZ-3 cell line is comparable to monocyte-derived dendritic cells in distinguishing allergens from irritants. Dutch Society for Immunology, Winter Meeting, 2002.
105. Caleffi M, Duarte Filho D, Skoniesky G, Bedin Jr A, Zignani JM, Antunes LP, Dias EC, Ashton-Prolla P, Weber B, Kivitz P, Graudenz MS, <b>Pohlmann PR</b>. The controversy of annual mammographic screening (AMS) for 40 to 69y-o women of Brazilian cohort of 10.000 underserved women. Can 2005 Annual San Antonio Breast Cancer Symposium (SABCS), 1999.
106. Sander E, Pohlmann PR, Campos Jr O, Monego H, Rivoire W. Grossmann OR, DiLeoni L, Loitzenbauer B, Kalakun L, Mans, DR, Schwartsmann G. Phase II Trial of Cisplatin and Decitabine in Patients with Advanced Cervical Cancer: a SOAD Trial. 1998 Annual Meeting of the American Society of Clinical Oncology (ASCO):374, 1998.
107. Maino M, Mans DR, DiLeoni L, Lago S, Almeida JK, Pohlmann PR, Schunemann H, Ferreira-Filho AF, Kalakun L, Schwartsmann G. Phase II Trial of a 21-day Continuous Infusion of Topotecan in Advanced Pancreatic Carcinoma: a SOAD Trial. 1998 Annual Meeting of the American Society of Clinical Oncology (ASCO):295, 1998.
108. Viegas MAV, DiLeoni L, Pohlmann PR, Loitzenbauer B, Kalakun L. Informed Consent in Early Clinical Trials with New Anticancer Agents: The SOAD Experience. 1998 Annual Meeting of the American Society of Clinical Oncology (ASCO):70a, 1998.
109. Schwartsmann G, Menke CH, Caleffi M, Xavier N, Ferreira Filho AF, Schunemann H, Koya R, Stroda PR, Pohlmann PR, Venegas LF, Kalakun L. Phase II Trial of Taxol (T), Doxorubicin (D) Plus G-CSF in Patients (PTS) With Metastatic Breast Cancer (MBC). 1996 Annual Meeting of the American Society of Clinical Oncology (ASCO):126, 1996.
110. Schwartsmann G, Mans DRA, Kalakun L, Grivich I, Schunemann, Ferreira Filho AF, Koya R, Lopes PRS, Pohlmann PR, Venegas LF, Pinto LB, Brunetto AL. Aumento dos níveis de etoposide no líquor em pacientes com gliomas refratários através do uso de altas-doses de tamoxifeno. 9º Congresso Brasileiro de Oncologia Clínica, 1995.
111. Schwartsmann G, Mans DRA, Machado V, Becker D, Grivicich I, Schunemann H, Pohlmann PR, Gottfridson M, Scaletzky A, Jung F, et al. Enhanced disposition of etoposide (VP-16) in the cerebrospinal fluid (CSF) by high-dose tamoxifen (Tmx) in patients (pts) with progressive malignant gliomas. 1995 Annual Meeting of the American Society of Clinical Oncology (ASCO):126, 1995.
112. Schwartsmann G, Scaletsky A, Jung F, Becker B, Gottfridson MJC, Machado VL, Pohlmann PR, Paglioli E, Oppitz P, Brunetto AL, Mans DRA. Farmacocinética do etoposide no líquido céfalo-raquidiano (LCR) de pacientes com gliomas refratários na presença de tamoxifeno. 14ª Semana Científica do Hospital de Clínicas de Porto Alegre:64, 1994.
113. Schwartsmann G, Scaletsky A, Jung F, Becker B, Gottfridson MJC, Machado VL, Pohlmann PR, Paglioli E, Oppitz P, Brunetto AL, Mans DRA. Farmacocinética do etoposide no líquido céfalo-raquidiano (LCR) de pacientes com gliomas refratários na presença de tamoxifeno. XIII Congresso Brasileiro de Cancerologia:17, 1994.
114. Schwartsmann G, Scaletzky A, Pohlmann PR, Jung FA, Becker D, Gottfridson MJC, Mans DRA. Enhanced Etoposide (VP-16) Retention in the Cerebrospinal Fluid (CSF) by Tamoxifen (TMX). Annals of Oncology 5(8):13-14, 1994.
115. Oderich G, Carvalhal EF, Pohlmann PR, Seligman B. Adenocarcinoma mucinoso de cólon em paciente masculino de 17 anos: relato de caso e revisão de literatura. 14ª Semana Científica do Hospital de Clínicas de Porto Alegre:66, 1994.
116. Pohlmann PR. Cancer Prevention by Medical Students, final report. 8º Congresso Brasileiro de Oncologia Clínica, 1993.
117. Pohlmann PR, Costa LA, Loss JF, Nicoletti C, Alves A, Dapper V, Ely D. Prevenção do câncer em estudantes de Medicina: relato final. 8º Congresso Brasileiro de Oncologia Clínica:67, 1993.
118. Costa LA, Pohlmann PR, Machado V, Torres G, Yi Jong Wu V, Azevedo S. Linfoma Não-Hodgkin: apresentação exclusiva em retroperitônio. 8º Congresso Brasileiro de Oncologia Clínica:54, 1993.
119. Pohlmann PR, Marzola B, Loss J, Polanczyk C, Zampese M. AIDS-Related Kaposi's Sarcoma in a Reference Hospital in the State of Rio Grande do Sul, Brazil: Survival Evaluation. VIII International Conference on AIDS / III STD World Congress, 1992.
120. Pohlmann PR, Marzola B, Loss J, Polanczyk C, Zampese M. AIDS-Related Kaposi's Sarcoma in a Reference Hospital in the State of Rio Grande do Sul, Brazil: Survival Evaluation. Proceedings: VIII International Conference on AIDS / III STD World Congress:123, 1992.
121. Sander E, Sprinz E, Zampese M, Marzola B, Pohlmann PR, Brunetto AL, Kronfeld M, Schwartsmann G. Oral Etoposide in AIDS-Related Kaposi's Sarcoma: a Phase II Trial. VIII International Conference on AIDS / III STD World Congress:76, 1992.
122. Pohlmann PR, Loss JF, Flores C, et al. Tabagismo em Porto Alegre: prevalência e o papel dos profissionais da saúde na prevenção. Actualización Científica. 8th Conferência Mundial sobre Tabagismo ou Saúde 2(6):4-5, 1992.
123. Pohlmann PR. AIDS-related malignancies. 7º Congresso Brasileiro de Oncologia Clínica, 1991.
124. Pohlmann PR. Cervix Cancer Mortality in Rio Grande do Sul, Brazil. 7º Congresso Brasileiro de Oncologia Clínica, 1991.
125. Pohlmann PR. Cancer Prevention: What do Medical Students know and how do they behave. 7º Congresso Brasileiro de Oncologia Clínica, 1991.
126. Pohlmann PR, Loss JF, Costa LA, Lara DR, Dapper V, Ely DR, Nicoletti C, Alves AA, Pólvora RP, Daudt AW. Prevenção do câncer: o que sabem e como se comportam as estudantes de Medicina. 7º Congresso Brasileiro de Oncologia Clínica:38, 1991.
127. Pohlmann PR, Loss JF, Wissmann Neto G, Marzola B, Vinholes J, Edelweiss MI, Robin Jr H, Sprinz E, Kronfeld M. Neoplasias associadas à Síndrome de Imunodeficiência Adquirida. 7º Congresso Brasileiro de Oncologia Clínica:17, 1991.
128. Pohlmann PR, Costa LA, Loss JF, Dietz J, Prolla JC. Mortalidade por câncer de colo uterino no Rio Grande do Sul: aspectos epidemiológicos. 7º Congresso Brasileiro de Oncologia Clínica:38, 1991.
129. Scroferneker ML, Ampessam M, Soares RS, Marques SMT, Cardoso AA, Horst JL, Loss JF, Pohlmann PR, Motta Neto AA, Edelweiss MI.. Inquérito sorológico com antígenos de P. brasiliensis, H. capsulatum e S. schenckii em ratos (Rattus rattus) habitantes de uma mina de carvão. Mina do Leão - Brazil. III Encontro Nacional de Microbiologia Ambiental:73, 1990.
130. Pohlmann PR. Tobacco Abuse in Porto Alegre: Prevalence and Health Providers Role on Prevention. 6º Congresso Brasileiro de Oncologia Clínica, 1989.
131. Pohlmann PR, Loss JF, Flores C, Bolzzoni A, Duncan BB. Tabagismo em Porto Alegre: prevalência e o papel dos profissionais da saúde na prevenção. 6º Congresso Brasileiro de Oncologia Clínica:25, 1989.

Book Chapters

1. Lynce F and Pohlmann PR. Premalignant Breast Conditions and in Situ Disease,Part 3 Solid Malignancies. In: Breast Cancer. Elsevier Inc, 90-7, 2018.
2. Pohlmann PR and Tan A. Metastatic Breast Cancer, Part 3 Solid Malignancies. In: Breast Cancer. Elsevier Inc, 77-9, 2018.
3. Watson G, Goff L, Shi C, Pohlmann PR. HER2 (ERBB2) in Gastric Cancer. In: Cancer Genome, 2015.
4. Schwartsmann G, Cornelio D, Pohlmann PR. Oncology Section [Modulo Oncologia]. In: Tratado de Clinica Medica. 3: Sao Paulo, Brazil, 2014.
5. Schwartsmann G, Cornelio D and Pohlmann PR. The Basis for Chemotherapy [Bases da Quimioterapia]. In: Tratado de Clinica Medica. 2: Sao Paulo, Brazil, 2007.
6. Zimmer A and Pohlmann PR. Humoral Immunity [Imunidade Humoral]. In: Imunologia Básica e Aplicada. 2: Sao Paulo, Brazil, 2007.
7. Girardi F and Pohlmann PR. Cellular Immunity [Imunidade Celular]. In: Imunologia Básica e Aplicada. 2. Segmento Farma: Sao Paulo, Brazil, 2007.
8. 8Girardi F and Pohlmann PR. Tumor Immunology [Imunologia Tumoral]. In: Imunologia Básica e Aplicada. 2. Segmento Farma: Sao Paulo, Brazil, 2007.
9. Pohlmann PR. Breast Cancer Molecular Biology [Biologia Molecular do Câncer de Mama]. In: A Mama em Imagens, 2006.
10. Pohlmann PR, Schwartsmann G. New Combined Therapies [Novas Combinações Terapêuticas]. In: Ferreira CG, Rocha JC. Oncologia Molecular. 1: São Paulo, Brazil, 2004.
11. Pohlmann PR. Chemoprevention [Químio-Prevenção]. In: Cancerologia para Leigo. 1: Porto Alegre, Brazil, 2001.
12. Eckert GU, Barrionuevo AA, Pohlmann PR. Lymphatic Organs [Órgãos Linfóides]. In: Imunologia Básica e Aplicada. 1: Porto Alegre, Brazil, 1998.
13. Pohlmann PR. The Cells of Immune System [Células do Sistema Imune]. In: Imunologia Básica e Aplicada. 1: Porto Alegre, Brazil, 1998.
14. Furian TQ and Pohlmann PR. Tumor Immunology [Imunologia dos Tumors]. In: Imunologia Básica e Aplicada. 1: Porto Alegre, Brazil, 1998.
15. Pohlmann PR. Tumor Immunology [Imunologia dos Tumores]. In: Notas de Imunologia: Porto Alegre, Brazil, 1996.
16. Crestani J, Pohlmann PR, Scroferneker ML. Type I Hypersensitivity reactions [Hipersensibilidade tipo I]. In: Notas de Imunologia: Porto Alegre, Brazil, 1996.
17. Pohlmann PR. The Cells of Immune System [Células do Sistema Imune]. In: Notas de Imunologia: Porto Alegre, Brazil, 1996.
18. Pohlmann PR. Lymphatic Organs [Órgãos Linfóides]. In: Notas de Imunologia: Porto Alegre, Brazil, 1996.
19. Pohlmann PR, Venegas LF, Ferreira Filho AF, Machado VL, Fleck J. Suspeita de Neoplasia. In: Medicina Interna: Do Diagnóstico ao Tratamento: Porto Alegre, Brazil, 1995.
20. Venegas LF, Pohlmann PR, Machado VL. Renal Cell carcinoma [Carcinoma de Células Renais]. In: Medicina Interna: Do Diagnóstico ao Tratamento: Porto Alegre, Brazil, 1995.
21. Pohlmann PR, Ferreira Filho AF, Schwartsmann G. Breast Cancer Chemotherapy [Quimioterapia do Câncer de Mama]. In: Mastologia Atual, 1994.